Antidiabetic and Antihyperlipidemic Effects of Myristica fragrans. in Animal Models

Figures & data

Table 1.. Effect of MF on metabolic parameters in high-cholesterol-fed rats.

Treatment	Dose	Triglycerides (mg/dL)	Cholesterol (mg/dL)
Vehicle	10 mL/kg	141.82 ± 23.24	294.31 ± 29.83
MF	50 mg/kg	154.63 ± 45.20	217.94 ± 19.52
	150 mg/kg	109.32 ± 13.49	190.54 ± 4.44**
	450 mg/kg	75.56 ± 8.34	98.25 ± 18.16**
Fenofibrate	100 mg/kg	64.01 ± 11.70	178.35 ± 11.00**

Compounds are administered orally for 7 days. Values are expressed as mean ± SEM from n = 5 to 6,

*p. < 0.005

**p. < 0.001 compared with vehicle treatment. MF, Myristica fragrans..

Figure 3 Effect of Myristica fragrans. on hepatic triglyceride secretion after the administration of tyloxapol in high cholesterol diet fed rats. Compounds were administered orally for 7 days. Each point represents mean ± SEM from n = 4 to 6. *p. < 0.005 and **p < 0.001 compared with vehicle treatment. MF, Myristica fragrans.; Feno, fenofibrate.

Figure 1 Effect of Myristica fragrans. on chlorpromazine-induced elevations of plasma glucose levels in mice. Compounds were administered orally for 7 days. Bars represent means ± SEM from n = 6. *p. < 0.005 and **p < 0.001 compared with vehicle treatment. MF, Myristica fragrans.; Fenofib, fenofibrate; Rosi, rosiglitazone; CPZ, chlorpromazine; Glim, glimepiride. ^#p. < 0.05 compared to vehicle/vehicle treated animals.

Figure 2 Effect of Myristica fragrans. on chlorpromazine-induced elevations of plasma triglyceride levels in mice. Compounds were administered orally for 7 days. Bars represent means ± SEM from n = 6. *p. < 0.005 and **p < 0.001 compared with vehicle treatment. MF, Myristica fragrans.; Fenofib, fenofibrate; Rosi, rosiglitazone; CPZ, chlorpromazine; Glim, glimepiride. ^#p. < 0.05 compared to vehicle/vehicle treated animals.